Drug Shortage Report for DOXORUBICIN HYDROCHLORIDE INJECTION
| Report ID | 174595 |
| Drug Identification Number | 02409275 |
| Brand name | DOXORUBICIN HYDROCHLORIDE INJECTION |
| Common or Proper name | DOXORUBICIN INJ |
| Company Name | TEVA CANADA LIMITED |
| Market Status | MARKETED |
| Active Ingredient(s) | DOXORUBICIN HYDROCHLORIDE |
| Strength(s) | 2MG |
| Dosage form(s) | SOLUTION |
| Route of administration | INTRAVESICAL INTRAVENOUS INTRAVESICAL INTRAVENOUS |
| Packaging size | 25 |
| ATC code | L01DB |
| ATC description | CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | |
| Actual start date | 2022-11-14 |
| Estimated end date | 2023-01-10 |
| Actual end date | 2023-01-10 |
| Shortage status | Resolved |
| Updated date | 2023-01-12 |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 30 NOVOPHARM COURT TORONTO, ONTARIO CANADA M1B 2K9 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v9 | 2023-01-12 | French | Compare |
| v8 | 2023-01-12 | English | Compare |
| v7 | 2022-12-22 | French | Compare |
| v6 | 2022-12-22 | English | Compare |
| v5 | 2022-12-01 | French | Compare |
| v4 | 2022-12-01 | English | Compare |
| v3 | 2022-11-15 | English | Compare |
| v2 | 2022-11-14 | French | Compare |
| v1 | 2022-11-14 | English | Compare |
Showing 1 to 9 of 9